Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.

doi:10.1080/07357907.2018.1499934

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.

Cancer investigation - 1 Jan 2018

Danzinger Sabine, Tan Yen Yen, Rudas Margaretha, Kastner Marie-Theres, Weingartshofer Sigrid, Muhr Daniela, Singer Christian F

Abstract excerpt

BRCA-1 mutation-associated triple-negative breast cancer (TNBC) has been hypothesized to exhibit a phenotype that is distinct from non-mutation carriers. We have analyzed immunohistochemically detected cytokeratins 5 and 14, epidermal growth factor receptor (EGFR), claudin (CLDN) 3, 4, and 7, and E-cadherin in 57 TNBC (32 BRCA1 and 8 BRCA2 tumors, 17 WT tumors). Positive staining of CLDN3 and negative EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to BRCA1 Protein
Share to ErbB Receptors
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Predictive Value of Tests

Share to ROC Curve

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 30142017
DOI: 10.1080/07357907.2018.1499934

Genes

BRCA1
EGFR
CLDN3
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.